Galectin Therapeutics Corporate Summary

Galectin Therapeutics

Forward Looking Statements

Galectin Therapeutics

This presentation contains, in addition to historical information, statements that look forward in time or that express

management s beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance,

and use words such as may, estimate, could, expect and others. They are based on our current expectations and are subject to risks and uncertainties that could cause actual results to differ materially

from those described in the statements. These statements include our plans, expectations and goals regarding drugs in development, clinical trials and regulatory approval for any of our drugs or treatments, related market opportunities for our

drugs, potential benefits of our drugs, estimates regarding cash and liquidity, and estimates regarding those impacted by NASH and liver fibrosis. Our plans, expectations and goals regarding drugs in development, clinical trials and regulatory

approval are subject to factors beyond our control. Our clinical trials may not begin or produce positive results in a timely fashion, if at all, and any necessary changes during the course of such trials could prove time consuming and costly. We

may have difficulty in enrolling candidates for testing and we may not be able to achieve the desired results. Upon receipt of regulatory approval for any drug or treatment, we may face competition with other drugs and treatments that are currently

approved or those that are currently in development, which could have an adverse impact on our ability to achieve revenues from the approved indication. Plans regarding development, approval and marketing of any of our drugs are subject to change at

any time based on the changing needs of our company as determined by management and regulatory agencies. Estimates regarding the potential benefits of our drugs and the potential market for any of our drugs may be inaccurate and, to the extent the

estimates are correct, we may not be successful in achieving revenues from any such drugs, as the successful marketing of any approved drugs will be subject to strong competition within the health care industry and patient and physician acceptance

of our drugs as safe, affordable and effective. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be impacted by our ability to manage costs and finance our continuing

operations. For a discussion of additional factors impacting our business, see our most recent Annual Report on Form 10-K and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent

events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Galectin Therapeutics NASDAQ:GALT 2

Galectin Therapeutics

Clinical stage biopharmaceutical company targeting fibrotic diseases and cancer with novel compounds that inhibit galectin proteins

Galectin proteins are important in the development and promotion of many fibrotic and neoplastic diseases

Currently in clinical trials with 2 compounds

GR-MD-02 for the indication of NASH (Fatty Liver Disease) with advanced liver fibrosis: Phase 1

GM-CT-01 targeting cancer, enhance ability of immune system to kill cancer cells: Phase 2a clinical trial in combination with peptide vaccine for advanced melanoma

2013 Galectin Therapeutics NASDAQ:GALT 3

Investment Highlights

Galectin Therapeutics

Proprietary Compounds

First in class, proprietary compounds that inhibit galectin proteins

Complex carbohydrate drugs with favorable safety profile

GR-MD-02: Potential to treat non-alcoholic steatohepatitis (NASH) and other causes of liver fibrosis

GM-CT-01: Potential to enhance cancer immunotherapy

Pre-clinical models show galectins are critical targets for intended diseases with mechanisms that would be novel in the

Large Market Opportunities

NASH and liver fibrosis indications would be first therapies for completely unmet medical needs, representing a multi-billion dollar market

Enhancing the ability of immune system to kill cancer cells is synergistic with many current and experimental therapies

Intellectual Property

Strong patent position

Sole ownership of compounds in development

Experienced Management Team

Management team has collective experience

in multiple biotech and pharmaceutical companies and relevant scientific areas

2013 Galectin Therapeutics

Galectin Therapeutics

Trading Symbol NasdaqCM: GALT

Corporate Headquarters Norcross, GA

Stock Price (3-6-2013); 52 Week

Range $3.66 $1.60 - $6.00

Shares Outstanding (3-6-2013) 16.1 million

Daily Volume (50-day average at 3-6-2013) 60,862

Market Capitalization (2-15-2013) $58.44 million

Cash & Equivalents (9-30-12) $11.1 million

Burn Funded through 2013

Enterprise Value (3-6-2013) $67.6 million

Fiscal Year Ends December 31th

Accounting Firm McGladrey LLP

2013 Galectin Therapeutics

Galectin Therapeutics

Science of Galectins

Regulatory and Clinical Plan

Competitive Positioning

Immune Enhancement in Cancer Therapy

Regulatory and Clinical Plan

Competitive Positioning

2013 Galectin Therapeutics NASDAQ:GALT 6

Galectin Proteins Are Critical Participants In Pathogenesis of Many Fibrotic and Neoplastic Diseases

Galectin Therapeutics

Secreted Galectin Proteins*

Bind to cell surface and matrix glycoproteins (galactose residues)

Modulate cell signaling

Promote cell-cell interactions

Promote cell-matrix interactions

Markedly Increased in:

GALECTINS PROMOTE PATHOLOGY

Galectin-3 is most prominent galectin

*Secreted in small amounts normally by a number of cells, predominantly macrophages

For more detail on science of galectins go to website: http://bit.ly/Z1z0OD

2013 Galectin Therapeutics NASDAQ:GALT

Galectin Inhibitors: A New Class of Pathology Modulators

Novel complex carbohydrate drugs that target

secreted and membrane-associated galectins by virtue of high molecular weight

Strongest binding to galectin-3, most

prominent galectin in disease processes

Binding to galectins disrupts function and modulates multiple cellular pathways

in pathology representing a new class of therapeutic agents.

Low toxicity potential as a carbohydrate with no toxic

Two classes of compounds under development, GM-CT and GR-MD; strong patent portfolio; company owned, no

Discovery program underway to identify synthetic carbohydrate drugs

2013 Galectin Therapeutics NASDAQ:GALT 8

Regulatory Status of Drugs

IND for use in combination with cancer chemotherapy

melanoma in combination with peptide vaccine

Has been shown generally safe in over 100 human subjects

GMP API and GMP drug product in large supply; Drug Master File on file with FDA

IND submitted January 2013 for use in patients with non-alcoholic steatohepatitis (NASH) with advanced fibrosis

Pharmacology, pharmacokinetics, toxicology, and safety pharmacology support advancement into clinical trials

GMP API and GMP drug product in place for phase 1 clinical trial

Received OK from FDA to proceed with Phase 1 clinical trial

For more on compounds and discovery program go to website: http://bit.ly/ZiqEk4

2013 Galectin Therapeutics NASDAQ:GALT 9